Patent ID: 8481055

Claim:
A method of enhancing the immunogenicity of a vaccine against Bacillus anthracis in a subject, comprising administering to the subject a therapeutically effective amount of an oligodeoxynucleotide consisting of the nucleic acid sequence set forth as SEQ ID NO: 23, an oligodeoxynucleotide consisting of the nucleic acid sequence set forth as SEQ ID NO: 24, and an oligodeoxynucleotide consisting of the nucleic acid sequence set forth as SEQ ID NO: 25; and administering to the subject a therapeutically effective amount of the vaccine against Bacillus anthracis , wherein the vaccine is (a) Anthrax Vaccine Adsorbed (AVA) or (b) recombinant Protective Antigen or Protective Antigen and an aluminum salt; thereby enhancing the immunogenicity of the vaccine.